Article
Mechanisms of Staphylococcus aureus survival of trimethoprim-sulfamethoxazole-induced thymineless death.
mBio - 13 Nov 2024
Gonsalves Lauren J, Tran Allyson, Gardiner Tessa, Freeman Tiia, Dutta Angshita, Miller Carson J, McNamara Sharon, Waalkes Adam, Long Dustin R, Salipante Stephen J, Hoffman Lucas R, Wolter Daniel J
Abstract excerpt
Trimethoprim-sulfamethoxazole (SXT) is commonly used to treat diverse Staphylococcus aureus infections, including those associated with cystic fibrosis (CF) pulmonary disease. Studies with Escherichia coli found that SXT impairs tetrahydrofolate production, leading to DNA damage, stress response induction, and accumulation of reactive oxygen species (ROS) in a process known as thymineless death (TLD). TLD...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
